Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2023-12-18 00:00:00 ET · period of report 2023-12-14 · accession 0001127602-23-029835 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-18 | 2023-12-14 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | F - Tax | $6.43 | -13.6K | 1.13M | -1% | -$87.4K |
| D | 2023-12-18 | 2023-12-14 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | A - Grant | $0.00 | +127.5K | 1.14M | +13% | $0 |
| D | 2023-12-18 | 2023-12-14 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | A - Grant | $0.00 | +595.0K | 595.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-14 | F | D | 13,592 | $6.43 | 1,128,859 | D | — | — | (F2) Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person. |
| 2 | Common | Common Stock | 2023-12-14 | A | A | 127,500 | $0.00 | 1,142,451 | D | — | — | (F1) Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| 3 | Derivative | Emp. Stock Option (Right to Buy) | 2023-12-14 | A | A | 595,000 | $0.00 | 595,000 | D | $6.43 · 2024-12-14 to 2033-12-14 | 595,000 Common Stock | (F3) Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |